Skip Navigation LinksHome > August 2010 - Volume 29 - Issue 8 > ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENIN...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181d9e653
Brief Reports

ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE

Diez-Domingo, Javier MD, PhD*†; Planelles-Cantarino, M. Victoria MD†; Baldo-Torrenti, Jose M. MD†; Ubeda-Sansano, Isabel MD, PhD†; Jubert-Rosich, Angels MD†; Puig-Barbera, Joan MD, PhD*; Gutierrez-Gimeno, M. Victoria PhD*

Supplemental Author Material
Collapse Box

Abstract

We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM197.

Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4–616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5–71.3) when MenC-CRM197 conjugate was used.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.